Group 1 - The first computing power experimental satellite, "Chenguang No. 1," will be launched, with plans for a space computing center to be established in about five years [1][10][14] - The National Space Administration released a plan for the high-quality and safe development of commercial space from 2025 to 2027, aiming for significant growth in the commercial space industry [1][16] - There are currently 13 commercial space-related companies listed on the Beijing Stock Exchange, with a total market value of 55.193 billion yuan as of November 28, 2025 [1][17][19] Group 2 - The information technology sector saw an average increase of 1.41% this week, with the median P/E ratio dropping to 65.5X [2][26][29] - The automotive industry’s median P/E ratio increased to 32.3X, indicating a positive trend in valuations [3][56] - The biotechnology sector's median P/E ratio decreased to 28.9X, reflecting a mixed performance across industries [2][37] Group 3 - Star Map Control (920116.BJ) reported a revenue increase of 15.57% and a net profit increase of 25.28% for the first three quarters of 2025 [21][23] - Fujida (920640.BJ) achieved a revenue growth of 16.62% and a net profit growth of 55.38% in the same period, indicating strong performance in the RF connector market [22][25] - The overall market capitalization of the technology sector rose from 448.767 billion yuan to 452.243 billion yuan, with a median market cap increase from 2.147 billion yuan to 2.155 billion yuan [3][43][49]

Group 1: Manufacturing Sector - November manufacturing PMI increased to 49.2%, up 0.2 percentage points from the previous month, but still below the seasonal average of 50.0%[14] - PMI for production rose by 0.3 percentage points to 50.0%; new orders improved by 0.4 percentage points to 49.2%[14] - Industrial raw material prices rebounded, with PMI purchase prices at 53.6% and factory prices at 48.2%, both up from previous values[22] Group 2: Non-Manufacturing Sector - November non-manufacturing PMI fell to 49.5%, down 0.7 percentage points, marking the first time this year below the expansion threshold[32] - Construction PMI improved slightly to 49.6%, with new orders index rising by 0.2 percentage points[24] - Policy-driven financial tools are less effective than in 2022, impacting service sector performance negatively[24] Group 3: Economic Indicators - Special bond issuance progress reached approximately 91.0% by the end of November, a significant increase of 10.1 percentage points from October[24] - Small enterprises showed a notable recovery in PMI, increasing by 2.0 percentage points, benefiting from improved US-China trade relations[22] - PPI is expected to narrow its year-on-year decline to around -2.0% in November, with a month-on-month increase of approximately 0.2%[22]

Investment Rating - The industry investment rating is optimistic (maintained) [1] Core Views - The insurance sector is preparing actively for the 2026 "opening red" period, with a focus on dividend insurance products, which are expected to outperform traditional insurance due to higher yield rates [6] - The brokerage sector continues to show high profitability, with wealth management, investment banking, and overseas business expected to drive earnings improvement [5][7] - The long-term interest rates are stabilizing at the bottom, which is expected to support the asset side logic and improve the liability cost for insurance companies [6] Summary by Sections Insurance Sector - The insurance companies are gearing up for the 2026 "opening red" with dividend insurance becoming the main product, offering a yield rate significantly higher than traditional insurance [6] - The market share of listed insurance companies is expected to increase due to the expansion of bank insurance channels and the release of "storage demand" [6] - The overall outlook for the liability side is optimistic, with potential improvements in the value rate of dividend insurance supported by rate adjustments and structural optimization [6] Brokerage Sector - The average daily trading volume of stock funds from January to November increased by 77.1% year-on-year, indicating strong market activity [7] - The China Securities Regulatory Commission has proposed to include commercial real estate in the public REITs pilot program, which is expected to enhance the market for REITs [7] - Major brokerage firms are expected to see significant ROE expansion under the current growth-oriented strategy, with low valuations presenting strategic allocation opportunities [7] Recommended Stocks - Recommended stocks include China Pacific Insurance, Ping An Insurance, China Life Insurance H, Huatai Securities, Guotai Junan, and others [8]

Investment Rating - The investment rating for the retail industry is "Positive" (maintained) [1] Core Views - The retail industry is experiencing a shift towards quality growth and long-term strategies, moving away from reliance on traffic bonuses [25][26] - The industry is focusing on emotional consumption themes, with high-quality companies in sectors like gold jewelry, offline retail, cosmetics, and medical aesthetics being highlighted as investment opportunities [5][29][30] Summary by Sections Retail Market Review - The retail industry index rose by 3.45% during the week of November 24-28, 2025, outperforming the Shanghai Composite Index by 2.05 percentage points [4][13] - The multi-format retail sector showed the highest growth this week, with a 6.18% increase, while the jewelry sector led the year-to-date performance with a 22.11% increase [18][19] Retail Insights: Brand Building and Technological Aesthetics - The 2025 Cosmetics Annual Conference highlighted the importance of brand building and technological aesthetics for domestic beauty brands to achieve growth [25][26] - Companies like Shiseido and Shanghai Jahwa are focusing on quality and profitability, while Elysian Group is transitioning from operational to technological drivers [26][27] Investment Recommendations - **Gold Jewelry**: Focus on brands with differentiated product offerings and consumer insights, recommending companies like Chow Tai Fook and Lao Pu Gold [5][29] - **Offline Retail**: Highlighting companies adapting to trends and exploring AI-enabled cross-border e-commerce, with recommendations for Yonghui Supermarket and Aiyingshi [5][30] - **Cosmetics**: Emphasizing brands that meet emotional value and safety innovation, recommending companies like Maogeping and Proya [5][30] - **Medical Aesthetics**: Targeting differentiated product manufacturers and expanding medical chains, recommending companies like Aimeike and Kedi-B [5][30] Company-Specific Insights - **Chow Tai Fook**: Achieved revenue of HKD 38.986 billion in FY2026H1, with a slight decline in revenue but a stable profit margin [36][37] - **潮宏基 (Chao Hong Ji)**: Reported a revenue increase of 28.4% in Q1-Q3 2025, with a strong performance in Q3 [39][40] - **永辉超市 (Yonghui Supermarket)**: Experienced a revenue decline of 22.2% in Q1-Q3 2025, but is undergoing a transformation towards quality retail [43][44]

Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Views - The report indicates that the pig price is supported by both supply and demand factors as the market enters the winter consumption peak, with expectations for a gradual increase in the price center [11] - The beef cycle is expected to maintain its prosperity, with a decrease in cattle inventory and high calf prices indicating cautious expansion in the breeding sector [20] - The report highlights the acceleration of pig breeding losses and the strengthening logic of domestic pet products, recommending several companies in the pig farming and pet sectors [24] Summary by Sections Weekly Observation - The average price of pigs in China as of November 28, 2025, is 11.20 yuan/kg, with a week-on-week decrease of 0.42 yuan/kg and a year-on-year decrease of 5.27 yuan/kg [11] - The average weight of pigs at market is 129.22 kg, showing a week-on-week increase of 0.41 kg and a year-on-year increase of 2.49 kg [11] - The report notes that winter consumption favors larger pigs, leading to an increase in average weights at market [11] Weekly Views - The report states that pig and piglet prices are in a loss situation, which may accelerate the culling of breeding sows [24] - The feed sector is benefiting from the post-cycle of poultry and livestock, with strong overseas demand supporting prices [24] - The pet sector is experiencing a rise in domestic brands due to consumption upgrades and tariff barriers [24] Market Performance (November 24-28) - The agricultural index outperformed the market by 0.17 percentage points, with the Shanghai Composite Index rising by 1.40% and the agricultural index rising by 1.57% [26] - Key stocks leading the market include Jin Xin Nong (+12.60%), Yuan Fei Pet (+8.39%), and Xi Wang Food (+7.57%) [26] Price Tracking (November 24-28) - The average price of pigs is 11.19 yuan/kg, down 0.45 yuan/kg from the previous week; piglet prices are 19.19 yuan/kg, up 0.04 yuan/kg [33] - The average wholesale price of beef is 66.39 yuan/kg, showing a week-on-week decrease of 0.18 yuan/kg [36] - Corn and soybean meal prices have increased, with corn futures at 2241.00 yuan/ton (up 2.66%) and soybean meal futures at 2459.00 yuan/ton (up 1.32%) [44]

Investment Rating - The investment rating for the computer industry is "Positive" (maintained) [1] Core Viewpoints - The commercial aerospace sector is expected to enter a period of rapid development, driven by continuous top-level design and intensive policy support from both domestic and international fronts [4][11] - The National Space Administration of China has launched an action plan for the high-quality and safe development of commercial aerospace from 2025 to 2027, aiming to integrate commercial aerospace into the national aerospace development framework [4][11] - The European Space Agency has approved its highest budget in history, totaling approximately €22.1 billion for the next three years, focusing on key scientific, exploratory, and technological projects [4][11] - Major overseas companies are intensively investing in space computing capabilities, indicating a significant trend in the industry [5][12] Summary by Sections Market Review - During the week of November 24 to November 28, 2025, the CSI 300 index rose by 1.64%, while the computer index increased by 3.08% [3][10] Industry Insights - The 14th Five-Year Plan emphasizes the cultivation and expansion of emerging and future industries, accelerating the development of strategic emerging industry clusters such as aerospace [4][11] - The establishment of a dedicated regulatory body for commercial aerospace in China is expected to enhance the industry's high-quality development and benefit the entire supply chain [4][11] Investment Recommendations - The report recommends companies such as Zhongke Xingtu, Aerospace Hongtu, Putian Technology, and Yaxin Security as beneficiaries of the commercial aerospace growth [6][13]

Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Views - The report highlights that Alibaba Cloud's Q3 revenue reached a new high, with a year-on-year growth of 34%, significantly surpassing the 26% growth in Q1 [5][13] - Capital expenditure for Alibaba in Q2 FY2026 was 31.501 billion, showing an 80.10% year-on-year increase, indicating strong investment in AI capabilities [5][13] - The report emphasizes the continuous growth in AI-related product adoption, with revenue from these products achieving triple-digit year-on-year growth for nine consecutive quarters [6][14] - Amazon is set to invest up to 50 billion for AI capacity expansion for U.S. government clients, marking a significant infrastructure development [7][15] - Google's TPU chips have been adopted by Meta, enhancing Google's competitive position in the chip market [7][16] Summary by Sections Section 1: Investment Insights - The report discusses the "siphoning effect" of AI, predicting continued global resonance in AI investments, with major players like Google and Meta increasing their capital expenditure [17] - It recommends focusing on three main lines: "optical networks, liquid cooling, and domestic computing power" [17] Section 2: Communication Data Tracking - As of October 2025, China had a total of 4.758 million 5G base stations, with a net increase of 507,000 stations compared to the end of 2024 [28] - The number of 5G mobile phone users reached 1.184 billion, reflecting a year-on-year growth of 18.99% [28] - In September 2025, the shipment of 5G mobile phones was 24.106 million units, accounting for 86.3% of total mobile phone shipments, with a year-on-year growth of 8.02% [28] Section 3: Operator Performance - China Mobile's cloud revenue for the first half of 2025 reached 56.1 billion, a year-on-year increase of 11.3% [47] - China Telecom's Tianyi Cloud revenue for the same period was 57.3 billion, growing by 3.8% year-on-year [47] - China Unicom's cloud revenue for the first three quarters of 2025 was 52.9 billion, showing steady growth [49]

Group 1 - The report suggests that after the recent market adjustment, growth stocks are expected to continue to outperform, with a focus on sectors such as military, media (gaming), AI applications, Hong Kong internet, and power equipment [3][12] - The financial engineering team has developed a sector rotation model, recommending a December industry portfolio that includes beauty care, social services, home appliances, oil and petrochemicals, retail, communication, transportation, automotive, media, and food and beverage [4][15] - Alibaba (9988.HK) is highlighted for its significant investment in AI infrastructure, which is expected to accelerate cloud business growth, alongside increased user traffic and revenue from e-commerce technology services [4][17] Group 2 - Zhongji Xuchuang (300308.SZ) is recognized as a global leader in optical modules, with a strong focus on cutting-edge research and commercial applications, gaining wide recognition from clients [4][20] - Yuekang Pharmaceutical (688658.SH) has several innovative drugs entering critical clinical or approval stages, indicating potential breakthroughs from research to commercialization [4][22] - Ximai Co., Ltd. (002956.SZ) continues to focus on the oat category, driving high growth through product structure adjustments and category innovations, benefiting from falling raw material prices [4][24] Group 3 - China Life Insurance (601628.SH) is expected to exceed expectations in its life insurance segment, with ongoing high growth in the bancassurance channel and improved investment returns [4][27] - Shangmei Co., Ltd. (2145.HK) is leveraging a multi-brand strategy and strong operational capabilities, with promising performance during the Double Eleven shopping festival [4][30] - Giant Network (002558.SZ) is anticipated to achieve new highs in key metrics due to seasonal events and successful game titles, indicating strong growth potential [4][33] Group 4 - Northern Huachuang (002371.SZ) is positioned to benefit from the growth of domestic semiconductor equipment and is expected to see significant order growth in 2026 [4][35] - Zhuoyi Information (688258.SH) is focusing on AI programming and related trends, with promising commercial prospects for its new products [4][37] - Midea Group (000333.SZ) is experiencing high growth in its ToB business and significant retail sales increases in its high-end brand strategy, contributing to sustained performance [4][40]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1][11]. Core Insights - The company has shown a significant improvement in its financial performance, with a narrowing of losses and a strong outlook for future profitability, particularly with the upcoming product launches and collaborations [4][6]. - The company is transitioning towards becoming a leader in physical world AI, with plans to introduce multiple new vehicle models and advanced technologies in the coming years [6][7]. Financial Performance Summary - In Q3 2025, the company achieved a revenue of 20.38 billion yuan, representing a year-on-year increase of 101.8% and a quarter-on-quarter increase of 11.5%. The gross margin was 20.1%, with a net loss of 380 million yuan, and an adjusted net loss of 150 million yuan, with expectations of profitability in Q4 2025 [4][5]. - The company expects Q4 2025 revenue to be between 21.5 billion and 23 billion yuan, a year-on-year increase of 33.5% to 42.8%, with vehicle deliveries projected between 125,000 and 132,000 units [6]. Revenue and Profit Forecast - Revenue projections for 2025-2027 are as follows: 77.54 billion yuan in 2025, 129.36 billion yuan in 2026, and 161.17 billion yuan in 2027, with corresponding Non-GAAP net profits expected to be -394 million yuan, 2.51 billion yuan, and 5.11 billion yuan respectively [4][7]. - The company’s price-to-sales (P/S) ratios for 2025, 2026, and 2027 are projected to be 1.9, 1.1, and 0.9 respectively, while the price-to-earnings (P/E) ratios for 2026 and 2027 are expected to be 57.4 and 28.2 respectively [4][7].

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company has increased its R&D investment, and its innovative pipeline is gradually entering a harvest period. The FDA has approved the clinical trial for the YKYY018 aerosol inhalation agent for the prevention and treatment of RSV infections. Despite facing pressure on its operating performance in 2025, the company is optimistic about its long-term growth potential due to its innovative layout and small nucleic acid technology platform [3][4] Financial Performance Summary - For the first three quarters of 2025, the company achieved revenue of 1.759 billion yuan, a year-on-year decrease of 41.20%. The net profit attributable to the parent company was -148 million yuan, down 170.56% year-on-year. The non-recurring net profit attributable to the parent company was -168 million yuan, a decrease of 182.95% year-on-year [3][4] - The company has adjusted the price of its "Ginkgo Leaf Extract Injection" at the end of 2024, which has impacted its performance. The R&D expenses have increased significantly, contributing to the net profit decline [3][4] - The sales expense ratio for the first three quarters of 2025 was 28.64%, down 7.37 percentage points; the management expense ratio was 10.67%, up 5.18 percentage points; the R&D expense ratio was 18.00%, up 9.27 percentage points; and the financial expense ratio was 0.59%, up 0.47 percentage points [3][4] Earnings Forecast - The revised earnings forecast for the company indicates net profits attributable to the parent company of -183 million yuan, -53 million yuan, and 69 million yuan for 2025, 2026, and 2027 respectively. The original forecasts were 51 million yuan, 206 million yuan, and 561 million yuan [3][4] - The expected EPS for 2025, 2026, and 2027 is -0.41 yuan, -0.12 yuan, and 0.15 yuan respectively, with the current stock price corresponding to P/E ratios of -60.6, -208.5, and 161.2 times [3][4] Innovative Pipeline Progress - The company is advancing its innovative drug pipeline, with key traditional Chinese medicine (TCM) drugs in the final review stage for NDA. The small nucleic acid innovative drugs YKYY015 and YKYY029 have received approval for clinical trials in the US and China, with ongoing Phase I trials domestically [4] - The RSV mRNA vaccine YKYY025 and VZV mRNA vaccine YKYY026 have also received approval for clinical trials in the US. The company has completed the Phase IIa clinical trial for its first domestic antisense nucleic acid drug for primary liver cancer [4]